Madrigal Pharmaceuticals Email Format

Pharmaceutical ManufacturingPennsylvania, United States501-1000 Employees

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com. 

✕

Access Insights for Madrigal Pharmaceuticals and Millions of Other Companies

Sign up for full access to Madrigal Pharmaceuticals information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory